Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Role of the addition of docetaxel to ADT in mHSPC

Joe O'Sullivan • 28 Jun 2022
EAU 2022
Genitourinary Cancer Prostate Cancer Docetaxel

Joe O’Sullivan, MD, Queen’s University, Belfast, UK, provides an overview of the role of doublet and triplet therapy in the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC), highlighting the improved responses seen with docetaxel in combination with androgen deprivation therapy (ADT). This interview took place at the European Association of Urology (EAU) Meeting 2022.

Disclosures

Prof. O’Sullivan reports the following conflicts of interest:
Personal fees for Advisory Board and Speaker’s bureau from: AAA/Novartis, Astellas, Bayer, Janssen, Sanofi

More from Joe O'Sullivan

0:58
Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer
Joe O'Sullivan • 28 Jun 2022
1:37
Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies
Joe O'Sullivan • 28 Jun 2022
1:26
UK prostate cancer challenges
Joe O'Sullivan • 8 Mar 2019
1:30
AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer
Joe O'Sullivan • 8 Mar 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals